POSC163 Cost-Utility Analysis of Empagliflozin in Chronic Heart Failure with Reduced Ejection Fraction: A UK Healthcare System Perspective

Abstract

Authors

YZ Tan E Birnie

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×